GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.

[1]  Tijana Krajisnik,et al.  A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. , 2008, European journal of endocrinology.

[2]  P. Moreau,et al.  Sequential Activation of Matrix Metalloproteinase 9 and Transforming Growth Factor &bgr; in Arterial Elastocalcinosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[3]  D. Fitzgerald,et al.  Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E2 , 2008, Annals of the rheumatic diseases.

[4]  J. Hoenderop,et al.  Calcium and phosphate homeostasis: Concerted interplay of new regulators , 2008, Annals of medicine.

[5]  L. Liaw,et al.  Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[6]  K. White,et al.  Two novel GALNT3 mutations in familial tumoral calcinosis , 2007, American journal of medical genetics. Part A.

[7]  K. White,et al.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. , 2007, Journal of musculoskeletal & neuronal interactions.

[8]  B. Kestenbaum.  PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphate Metabolism in the Setting of Chronic Kidney Disease: Significance and Recommendations for Treatment , 2007, Seminars in dialysis.

[9]  D. Simionescu,et al.  Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification. , 2007, The American journal of pathology.

[10]  Jason R. Stubbs,et al.  PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Role of Fibroblast Growth Factor 23 in Phosphate Homeostasis and Pathogenesis of Disordered Mineral Metabolism in Chronic Kidney Disease , 2007, Seminars in dialysis.

[11]  J. Uribarri.  PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphorus Homeostasis in Normal Health and in Chronic Kidney Disease Patients with Special Emphasis on Dietary Phosphorus Intake , 2007, Seminars in dialysis.

[12]  E. Sprecher.  Tumoral calcinosis: New insights for the rheumatologist into a familial crystal deposition disease , 2007, Current rheumatology reports.

[13]  J. Uitto,et al.  Aberrant mineralization of connective tissues in a mouse model of pseudoxanthoma elasticum: systemic and local regulatory factors. , 2007, The Journal of investigative dermatology.

[14]  K. Kleesiek,et al.  SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. , 2007, Clinical chemistry.

[15]  M. Econs,et al.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  P. Beck‐Peccoz,et al.  Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis , 2007, Journal of Human Genetics.

[17]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[18]  Y. Frishberg,et al.  Hyperostosis–Hyperphosphatemia Syndrome: A Congenital Disorder of O‐Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23 , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  M. Econs,et al.  Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  Daniel L. Koller,et al.  The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  T. Strom,et al.  Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis , 2006, Journal of Biological Chemistry.

[22]  N. Powe,et al.  Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. , 2006, Kidney international.

[23]  L. Matrisian,et al.  Matrix Metalloproteinase Inhibition Attenuates Aortic Calcification , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[24]  C. Masters,et al.  Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* , 2006, Journal of Biological Chemistry.

[25]  K. White,et al.  The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. , 2006, Endocrine reviews.

[26]  Stylianos E. Antonarakis,et al.  Mendelian disorders deserve more attention , 2006, Nature Reviews Genetics.

[27]  I. Dianzani,et al.  Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family , 2006, Journal of Clinical Pathology.

[28]  M. Indelman,et al.  Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred , 2006, Journal of Human Genetics.

[29]  C. Götting,et al.  Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. , 2006, Clinical chemistry.

[30]  M. Pfeffer,et al.  Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.

[31]  Y. Takeuchi,et al.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  M. Indelman,et al.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification , 2005, Human Genetics.

[33]  S. Mooney,et al.  Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. , 2005, Endocrinology.

[34]  I. Rosner,et al.  Calcinosis in rheumatic diseases. , 2005, Seminars in arthritis and rheumatism.

[35]  R. Bergman,et al.  Absence of Intraepidermal Glycosyltransferase ppGalNac-T3 Expression in Familial Tumoral Calcinosis , 2005, The American Journal of dermatopathology.

[36]  M. Econs,et al.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. , 2005, The Journal of clinical endocrinology and metabolism.

[37]  K. White,et al.  FGF23 and disorders of phosphate homeostasis. , 2005, Cytokine & growth factor reviews.

[38]  S. Mooney,et al.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[39]  R. Shimkets,et al.  Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[40]  P. Orlik,et al.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.

[41]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[42]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[43]  S. Kwak,et al.  Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell , 2002, Journal of Cancer Research and Clinical Oncology.

[44]  M. Nishimura,et al.  N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers , 2002, British Journal of Cancer.

[45]  M J Bissell,et al.  The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. , 2001, Development.

[46]  D. Howell,et al.  Basic calcium phosphate crystals up-regulate metalloproteinases but down-regulate tissue inhibitor of metalloproteinase-1 and -2 in human fibroblasts. , 2001, Osteoarthritis and cartilage.

[47]  L. Wenger,et al.  Induction of Matrix Metalloproteinase-8 in Human Fibroblasts by Basic Calcium Phosphate and Calcium Pyrophosphate Dihydrate Crystals: Effect of Phosphocitrate , 2001, Connective tissue research.

[48]  C. Adams,et al.  Inorganic phosphate induces apoptosis of osteoblast-like cells in culture. , 2000, Bone.

[49]  H. Takano,et al.  Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. , 1999, Cancer research.

[50]  O. Cussenot,et al.  FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells , 1999, International journal of cancer.

[51]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[52]  P. Christopherson,et al.  Basic calcium phosphate crystals induce synthesis and secretion of 92 kDa gelatinase (gelatinase B/matrix metalloprotease 9) in human fibroblasts , 1998, Annals of the Rheumatic Diseases.

[53]  S. Werner,et al.  Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. , 1996, The Biochemical journal.

[54]  E. Bennett,et al.  cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. , 1996, The Journal of biological chemistry.

[55]  R. Slavin,et al.  Familial Tumoral Calcinosis: A Clinical, Histopathologic, and Ultrastructural Study with an Analysis of its Calcifying Process and Pathogenesis , 1993, The American journal of surgical pathology.

[56]  B. Eisenstein,et al.  Tumoral calcinosis revisited — common and uncommon features , 1988, European Journal of Pediatrics.

[57]  M. Szczepańska-Konkel,et al.  Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. , 1986, The Journal of biological chemistry.

[58]  H. DeLuca,et al.  Elevated serum calcitriol concentrations do not fall in response to hyperphosphatemia in familial tumoral calcinosis. , 1985, American journal of diseases of children.

[59]  S. Fukumoto.  Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23. , 2008, Internal medicine.

[60]  A. Buffa,et al.  Hyperphosphatemia: effects on bone metabolism and cardiovascular risk. , 2007, Journal of endocrinological investigation.

[61]  I. Alferiev,et al.  Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders , 2004, Pharmaceutical Research.

[62]  S. Werner,et al.  Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. , 2004, European journal of cell biology.

[63]  Lawrence A Tabak,et al.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. , 2003, Glycobiology.